Peng Juqin, Chen Xiaoxiao, Hou Min, Yang Kuo, Yang Bing, Wang Pan, Du Yang, Yu Qingyuan, Ren Junguo, Liu Jianxun
Beijing Key Laboratory of Pharmacology of Traditional Chinese Medicine, Institute of Basic Medical Sciences, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Beijing University of Chinese Medicine, Beijing, China.
Front Pharmacol. 2022 Feb 28;13:794405. doi: 10.3389/fphar.2022.794405. eCollection 2022.
The Feilike mixture (FLKM) is a valid prescription that is frequently used to assist in the clinical treatment of pneumonia. However, the mechanisms of its effects remain unclear. First, through literature evaluation, it was preliminarily determined that FLKM improved clinical symptoms, regulated immune inflammation response and ameliorated pulmonary function. Then, database search and literature mining, 759 targets of the 104 active compounds of FLKM were identified. The component-target (CT) network showed that the key active compositions were resveratrol, stigmasterol, beta-sitosterol, sesamin, and quercetin. 115 targets overlapped with pneumonia-related targets. The protein-protein interaction (PPI) network identified TNF, AKT1, IL6, JUN, VEGFA and MAPK3 as hub targets. KEGG analyses found that they were mainly enriched in immune related pathway. Next, experiment, we observed that FLKM ameliorated pathological injury of lung tissue and reduced neutrophil infiltration in rats with LPS-induced pneumonia. And FLKM decreased the concentration of TNF- and IL-6 in BALF and downregulated the expression of p38MAPK, AKT and VEGFA in lung tissue. Finally, Molecular docking tests showed tight docking of these predicted targeted proteins with key active compounds. Molecular dynamics simulation was employed to assess stability and flexibility of receptor-ligand. Among them, AKT1- stigmasterol bound more stably, and their binding free energies were -47.91 ± 1.62 kcal/mol. This study revealed core compositions and targets for FLKM treating pneumonia and provided integrated pharmacological evidence to support its clinical efficacy.
肺力咳合剂(FLKM)是一种有效的方剂,常用于辅助肺炎的临床治疗。然而,其作用机制尚不清楚。首先,通过文献评估,初步确定肺力咳合剂可改善临床症状、调节免疫炎症反应并改善肺功能。然后,通过数据库检索和文献挖掘,确定了肺力咳合剂104种活性成分的759个靶点。成分-靶点(CT)网络显示,关键活性成分是白藜芦醇、豆甾醇、β-谷甾醇、芝麻素和槲皮素。115个靶点与肺炎相关靶点重叠。蛋白质-蛋白质相互作用(PPI)网络确定肿瘤坏死因子(TNF)、蛋白激酶B1(AKT1)、白细胞介素6(IL6)、原癌基因蛋白(JUN)、血管内皮生长因子A(VEGFA)和丝裂原活化蛋白激酶3(MAPK3)为核心靶点。京都基因与基因组百科全书(KEGG)分析发现,它们主要富集于免疫相关途径。接下来,通过实验,我们观察到肺力咳合剂可改善脂多糖诱导的肺炎大鼠的肺组织病理损伤并减少中性粒细胞浸润。肺力咳合剂还降低了支气管肺泡灌洗液(BALF)中TNF-和IL-6的浓度,并下调了肺组织中p38丝裂原活化蛋白激酶(p38MAPK)、AKT和VEGFA的表达。最后,分子对接试验表明这些预测的靶向蛋白与关键活性成分紧密对接。采用分子动力学模拟来评估受体-配体的稳定性和灵活性。其中,AKT1-豆甾醇结合更稳定,其结合自由能为-47.91±1.62千卡/摩尔。本研究揭示了肺力咳合剂治疗肺炎的核心成分和靶点,并提供了综合药理学证据来支持其临床疗效。